Cigna Group Reports $71.7 Billion Revenue in Q2 2026, 7% Increase Year-Over-Year

The Cigna Group reported a total revenue of $71.7 billion for the second quarter of 2026, marking a 7% increase from $67.2 billion in the same period last year. For the first half of 2026, revenues reached $140.2 billion, up 6% from $132.7 billion in the first half of 2025. The growth was primarily driven by a 7% increase in pharmacy revenues, which totaled $57.2 billion, and a 6% rise in fees and other revenues, amounting to $4.4 billion. However, premiums decreased by 8% in the second quarter, totaling $9.9 billion, and fell 10% for the first half, reflecting the impact of the divestiture of certain businesses to Health Care Services Corporation in March 2025.

Net income for the second quarter was $1.9 billion, an increase of 15% compared to $1.6 billion in the prior year. For the first half, net income rose 23% to $3.7 billion from $3.0 billion. Shareholders' net income per diluted share increased to $6.29 from $5.71 in the second quarter of 2025, and for the first half, it rose to $12.55 from $10.55. The effective tax rate for the second quarter was 16.9%, down from 19.2% a year earlier, primarily due to tax benefits related to equity investments.

Operationally, Cigna's medical customer base grew by 2% year-over-year, reaching approximately 18.4 million, driven by increases in the Middle Market and Select segments. However, the U.S. Healthcare segment saw a 5% decline in customers, attributed to the ongoing transition following the HCSC transaction. The company also reported a 9% increase in medical costs for the second quarter, reflecting higher utilization and unit costs, while the medical care ratio improved slightly to 84.5% from 83.2% in the previous year.

Strategically, Cigna announced its planned exit from the Individual and Family Plans medical business effective January 1, 2027, as part of its ongoing optimization efforts. The company has also been focusing on enhancing its operational efficiency through a strategic optimization program, which has incurred costs of $450 million in the first half of 2026. Looking ahead, Cigna anticipates continued growth in its pharmacy and specialty services, although it remains cautious about the potential impacts of regulatory changes and market conditions on its operations and financial performance.